Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Oncotarget · 2016 · PMC4823037 · PMID 26575171

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

In summary, both phase III trials failed to show prolongation of OS by BEV-containing treatment regimens, whereas significant and marginally significant PFS benefits were described, and contradicting results were obtained when evaluating quality of life or neurocognition (no data within the AVAglio trial), respectively [ 33 , 34 ].

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.